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Abstract
In chronic inflammatory diseases, such as rheumatoid arthritis,
inflammation acts as an independent cardiovascular risk factor
and the use of anti-inflammatory drugs, such as anti-tumor
necrosis factor alpha (anti-TNFα), may decrease this risk. The
phagocytosis of oxidized low density lipoproteins (LDLs)
accumulated in the subendothelium by mononuclear cells
influences atherosclerosis and depends on CD36 expression.
We investigated the role of TNFα and adalimumab, a human
anti-TNFα monoclonal antibody widely used in human
pathology, in CD36 expression in human monocytes. Human
monocytes were prepared by adherence from whole-blood
buffy-coat fractions from healthy donors. CD36 expression was
assessed by RT-PCR and flow cytometry, with various TNFα or
adalimumab concentrations. Implication of peroxisome
proliferator-activated receptor (PPAR)γ in the regulation of
CD36 expression was assessed using specific inhibitor or gel
shift assays. The impact of redox signaling was investigated
using quantification of reactive oxygen species, antioxidant and
a NADPH oxidase inhibitor. The F(ab')2 fragment of adalimumab
was isolated and its effect was analyzed. TNFα inhibits both
CD36 membrane expression and mRNA expression. This
inhibition involves a reduction in PPARγ activation. In contrast,
adalimumab increases both CD36 membrane expression and
mRNA expression. This induction is independent of the Fc
portion of adalimumab and involves redox signaling via NADPH
oxidase activation. CD36 expression on human monocytes is
inhibited by TNFα and independently increased by adalimumab.
These data highlight that pro-inflammatory cytokines and their
specific neutralization influence the expression of cellular
receptors implicated in atherosclerosis. Further studies are
needed to investigate the clinical implications of these results in
accelerated atherosclerosis observed in rheumatoid arthritis.
Introduction
In chronic inflammatory diseases, such as rheumatoid arthritis
(RA), systemic inflammation appears as an independent risk
factor, contributing to increased cardiovascular mortality [1].
This high cardiovascular mortality reveals the existence of
accelerated atherosclerosis, the pathogenesis of which may
be associated with multiple factors, such as dyslipidemia,
deterioration of insulin sensitivity, hyperhomocysteinemia and
endothelial dysfunction [2,3]. Control of systemic inflammation
using conventional drugs, such as methotrexate, or biological
therapies, such as anti-tumor necrosis factor alpha (anti-
TNFα), provides a means of preventing high cardiovascular
mortality among RA patients [4,5].
ABCA1 = ATP-binding cassette transporters A1; DPI = diphenylene iodonium chloride; FcγR = Fc gamma receptor; HBSS = Hanks balanced salt 
solution; IL = interleukin; LDLs = low density lipoproteins; M-SFM = macrophage-serum-free medium; Nrf2 = nuclear factor erythroid 2-related factor 
2; PBMC = peripheral blood mononuclear cell; PBS = phosphate-buffered saline; PPAR = peroxisome proliferator-activated receptor; RA = rheuma-
toid arthritis; ROS = reactive oxygen species; RT-PCR = reverse transcription PCR; SD = standard deviation; SRA = scavenger receptor class A; 
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Of the various molecular agents of inflammatory response,
proinflammatory cytokines, and TNFα in particular, play a
major role in the development of atherosclerosis. TNFα pro-
motes the expression of adhesion molecules, such as vascular
cell adhesion molecule-1, E-selectin and intercellular adhesion
molecule, necessary for the flow of leucocytes into the sub-
endothelial tissue [6]. It also promotes production of other
proinflammatory cytokines and chemokines, such as IL1, IL6
and IL8. Along with interferon-γ, TNFα plays an important role
in atheroma plaque rupture by inducing overexpression of
matrix metalloproteinases by macrophages, leading to degra-
dation of the collagen matrix vital to plaque stability [7]. In apol-
ipoprotein-E deficient mice, which provide a valid research
model for atherosclerosis, inactivation of the gene encoding
TNFα significantly reduces the size of atheroma plaques [8,9].
Treating these mice with a fusion protein comprising a type I
TNF receptor, neutralizing the TNFα, also significantly reduces
the size of atheroma plaques [9,10]. In humans, neutralizing
TNFα using an anti-TNFα monoclonal antibody corrects
endothelial dysfunction observed in chronic inflammatory dis-
eases, such as RA and systemic vasculitis [11,12]. Further-
more, TNFα neutralization using either a fusion protein
comprising a type II TNFα receptor or an anti-TNFα mono-
clonal antibody is associated with a reduction in the incidence
of first cardiovascular events in RA patients [5].
Among the cellular agents of inflammatory response, mononu-
clear cells play an essential role in the development of athero-
sclerosis. Local inflammatory reaction within the atheroma
plaque follows the phagocytosis by mononuclear cells of oxi-
dized low density lipoproteins (LDLs) accumulated in the sub-
endothelium [7]. This phagocytosis of oxidized LDLs is caused
by scavenger receptors, in particular CD36 and scavenger
receptor class A (SRA), and results in the formation of foam
cells [13-15]. CD36 is strongly expressed by macrophages
within the atheroma plaque [16]. The accumulation of oxidized
LDLs by macrophages from subjects naturally deficient in
CD36 appears clearly reduced [17]. Different cytokines
essential for the regulation of inflammatory and immune
responses modulate the expression of CD36 by macro-
phages. IL4 induces the expression of CD36 by activating the
regulatory transcription factor peroxisome proliferator-acti-
vated receptor (PPAR)γ [18], while transforming growth factor
beta represses it [19]. Redox signaling also plays a major role
in regulating the expression of CD36. Various products
derived from lipid peroxidation induce expression of CD36 by
activating regulatory transcription factors, such as nuclear fac-
tor erythroid 2-related factor 2 (Nrf2), while vitamin E
represses it [20-22]. Some therapeutic agents used in human
pathology for their anti-inflammatory properties appear to mod-
ulate expression of CD36 by monocytes/macrophages and
dendritic cells: aspirin induces expression of CD36 by human
macrophages while dexamethasone induces expression of
CD36 by dendritic cells [23,24].
These data highlight the key roles played by TNFα, mononu-
clear cells and scavenger receptors in the development of
accelerated atherosclerosis observed in chronic human
inflammatory diseases. New therapeutic agents that specifi-
cally neutralize TNFα have proved to be efficacious in the con-
trol of systemic inflammation and in reducing the incidence of
cardiovascular events in RA patients [5]. These factors have
prompted us to test the hypothesis that CD36 expression in
human monocytes is regulated by TNFα and by adalimumab,
a human anti-TNFα monoclonal antibody widely used in
human pathology. Our work shows differential regulation of
CD36 expression by TNFα and adalimumab. Characterizing
the mechanisms involved in this differential regulation of CD36
expression may have implications for the prevention of high
cardiovascular mortality observed in chronic inflammatory
diseases.
Materials and methods
Isolation and culture of human monocytes
Peripheral blood mononuclear cells (PBMCs) were isolated
from the cytapheresis residues obtained from healthy donors
by density gradient on Lymphoprep (AbCys, Paris, France)
according to the manufacturer's instructions. The monocytes
were isolated from the PBMC by adhesion [25]. The PBMCs
were cultured in macrophage-serum-free medium (M-SFM;
Gibco Invitrogen, Cergy Pontoise, France) supplemented with
L-glutamine at a concentration of 107 cells/ml for 1.5 hours at
37°C with 5% CO2 in a humid atmosphere. The non-adherent
cells were eliminated via three PBS (Eurobio, Les Ulis, France)
washes. The adherent cells (>85% of monocytes [26]) were
then cultivated in M-SFM in 96-well trays (Becton Dickinson,
Le Pont-De-Claix, France) with 0.125 × 106 monocytes/0.125
ml for reactive oxygen species (ROS) assay, in 24-well trays
with 0.5 × 106 monocytes/0.5 ml for flow cytometry tests and
gel shift assays, and in 12-well trays with 106 monocytes/ml for
reverse transcription (RT)-PCR tests.
Isolation of F(ab')2, the antigen binding fragment, from 
adalimumab
The isolation of the F(ab')2 fragment from adalimumab (Abbott
France, Rungis, France), a human anti-TNFα IgG1 monoclonal
antibody, was carried out by pepsin digestion using the Immu-
noPure F(ab')2 Preparation Kit (Pierce by Interchim,
Montluçon, France) according to the manufacturer's instruc-
tions. The purity of the F(ab')2 fragment obtained after adali-
mumab digestion was verified by migration of the final
specimen on a 12% denaturant acrylamide gel, according to
the manufacturer's instructions.
Quantification of membrane expression of CD36 using 
flow cytometry
In time-course experiments, monocytes were incubated for 6
to 12 and 24 h with M-SFM alone or with M-SFM containing
TNFα (10 ng/ml) or adalimumab (1 μg/ml). In additional
assays, monocytes were incubated for 24 h with M-SFM aloneAvailable online http://arthritis-research.com/content/9/2/R22
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or with M-SFM containing: human recombinant TNFα at
increasing concentrations (0.1, 1 or 10 ng/ml; BD Bio-
sciences Pharmingen, Le Pont-De-Claix, France); or a combi-
nation of TNFα (10 ng/ml) or adalimumab (1 μg/ml; a
biologically relevant concentration used in human therapeutics
[27]; Abbott France) with either TNFα (10 ng/ml), GW9662
(2 μM; Cayman Chemicals by Spi-Bio, Montigny le Breton-
neux, France), Trolox® (1 μM; Sigma-Aldrich, Saint Quentin
Fallavier, France), or diphenylene iodonium chloride (DPI; 1
μM; Calbiochem by VWR International, Fontenay sous Bois,
France). Rituximab, a human anti-CD20 IgG1 monoclonal anti-
body (Roche, Meylan, France) was used at the same concen-
tration as adalimumab (1 μg/ml) as control antibody. To
investigate the relative contributions of Fab and Fc fragments
in the induction of CD36 membrane expression by adalimu-
mab, monocytes were incubated for 24 h with the F(ab')2 frag-
ment of adalimumab (0.8 μg/ml). Quantification of membrane
expression of CD36 on monocytes was carried out using flow
cytometry according to the following protocol: the monocytes
were washed once with PBS and then incubated for 15 min-
utes at 4°C in 5 mM PBS EDTA and collected by aspirating
and refilling the wells. The monocytes were then incubated
with the anti-CD36 monoclonal antibody labeled with phyco-
erythrin (BD Bioscience Pharmingen), used at a ratio of 10 μl
per 0.5 × 106 cells. The background staining was evaluated
using a control isotype labeled with phycoerythrin (BD Bio-
science Pharmingen) (data not shown). The region of interest
of the monocyte population, comprising over 3,000 cells, was
isolated on morphological criteria of cell size and granularity.
The presence of strong CD14 expression, a characteristic of
monocytes, was verified within the region of interest (data not
shown). The quantification of membrane expression of CD36
was obtained from the geometric mean of the fluorescence
measured [23].
Study of PPARγ activation by gel-shift assay
Monocytes were incubated with M-SFM alone or with M-SFM
containing TNFα (10 ng/ml) for 5, 30 or 60 minutes and then
stimulated, or not, by a synthetic ligand of PPARγ, rosiglita-
zone (5 μM). Nuclear proteins were then isolated according to
the following procedure: the monocytes were lysed at 4°C in
a hypotonic buffer (10 mM Hepes Free Acid® (Sigma-Aldrich),
10 mM KCl, 0.5 mM EDTA, 1 mM MgCl2, 0.1 mM EGTA) sup-
plemented by anti-proteases (Complete®, Roche Diagnos-
tics). Igepal®  (10%; Sigma-Aldrich) was added. The
cytoplasmic extracts (supernatants) were isolated after centrif-
ugation and the pellet was replaced in a hypertonic buffer, (20
mM Hepes Free Acid®, 400 mM NaCl, 0.5 mM EDTA, 1 mM
MgCl2, 0.1 mM EGTA) supplemented with anti-proteases
(Complete®) in order to extract the nuclear proteins. The pro-
teins were dosed according to the Bradford method.
The oligonucleotide (Santa Cruz Biotechnology by Tebu-Bio,
Le Perray en Yvelines, France) used for the shift had the fol-
lowing sequence: 5'-CAAAACTAGGTCAAAGGTCA-3', with
the underlined sequence corresponding to the PPAR DNA
consensus binding sequence. It was labeled with [γ-32P]ATP
at 37°C using T4 polynucleotide kinase (Promega France,
Charbonnières-les-Bains, France) and purified on appropriate
columns (Quiagen, Courtaboeuf, France). The probe was
labeled at 30,000 to 40,000 cpm/μl.
For the DNA protein reaction, 3 μg of proteins mixed at ambi-
ent temperature with the binding buffer (2 mM Hepes Free
Acid®, 50 mM NaCl, 0.5 mM EDTA, 1 mM MgCl2, 4% glycerol,
2 μg/ml bovine serum albumin, 0.5 mM dithiothreitol), 3 μl of
labeled oligonucleotides and 0.3 μg of poly (dI-dC) (Sigma-
Aldrich) were added in a final volume of 25 μl and incubated
for 20 minutes at room temperature. The specimens were
placed on 5% non-denaturing acrylamide gel and set to
migrate for 2.5 h at 180 V. The gel was dehydrated under vac-
uum and exposed by autoradiography.
Analysis of CD36 mRNA expression using real time PCR
Monocytes were incubated for 4 h with M-SFM alone or with
M-SFM containing either TNFα (10 ng/ml), adalimumab (1 μg/
ml), or rosiglitazone (5 μM) with or without pretreatment with
TNFα (10 ng/ml). The monocytes were lysed in TRIzol® Rea-
gent (Invitrogen) and the mRNA was extracted using the chlo-
roform/isopropanol/ethanol standard procedure. To ascertain
that RNA preparations were genomic DNA-free, a negative
control reaction was systematically included in which the sam-
ple was substituted with water.
PCR for CD36 and β-actin cDNA was performed with the LC
FastStart DNA master SYBR Green I (Roche Diagnostics).
Amplification and detection were performed in a LightCycler®
system (Roche Diagnostics) as follows, according to the man-
ufacturer's instructions. Reaction mixture (20 μl) was incu-
bated initially for 8 minutes at 95°C to activate the Fast Start
Taq DNA; amplifications were performed for 40 cycles (15 s
at 95°C and 30 s at 69°C) for CD36 and β-actin. The primers
were designed with the software Primer Express (Applied Bio-
systems, Foster City, USA). The primers were: 5'-TGT-AAC-
CCA-GGA-CGC-TGA-GG-3' (sense) and 5'-GAA-GGT-
TCG-AAG-ATG-GCA-CC-3' (antisense) for CD36; 5'-CCT-
CAC-CCT-GAA-GTA-CCC-CA-3' (sense) and 5'-TGC-CAG-
ATT-TTC-TCC-ATG-TCG-3' (antisense) for β-actin.
Real-time PCR data are represented as Ct values, where Ct is
defined as the crossing threshold of PCR using Light-Cycler®
Data Analysis software. For calculating relative quantification
of CD36 mRNA expression, we used the following procedure:
ΔCtCD36 = CtSample - CtControl and ΔCtβ-actin = CtSam-
ple - CtControl; then, ΔΔCt represents the difference between
ΔCtβ-actin and ΔCtCD36 calculated by the formula ΔΔCt =
ΔCtβ-actin - ΔCtCD36; finally, the N-fold differential expres-
sion of CD36 mRNA samples compared to the control is
expressed as 2ΔΔCt.Arthritis Research & Therapy    Vol 9 No 2    Boyer et al.
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Quantification of reactive oxygen species production
Monocytes were incubated for 1 h with Hanks balanced salt
solution (HBSS; Eurobio, Les Ulis, France) alone or with
HBSS containing adalimumab (1 μg/ml), TNFα (10 ng/ml) or
F(ab')2 (0.8 ng/ml). ROS production was quantified by chemi-
luminescence in the presence of 5-amino-2,3-dihydro-1,4-
phthalazinedione (66 mM; Luminol®, Sigma-Aldrich) using a
thermostatically (37°C) controlled luminometer (Wallac 1420
Victor2, Finland) [26]. The generation of chemiluminescence
was monitored continuously for 1 h. Results are expressed as
total chemiluminescence emission (area under the curve).
Statistical analysis
All flow cytometry and real time PCR experiments were per-
formed at least three times. The values are expressed as the
mean ± standard deviation (SD). A Wilcoxon test was used to
assess the significance of differences between two condi-
tions. All p values are two-sided, and p values less than 0.05
are considered significant.
Results
Regulation of CD36 membrane expression by TNFα and 
adalimumab
To study the effect of TNFα on the regulation of membrane
expression of CD36, monocytes were treated with TNFα (10
ng/ml) for increasing periods of time and membrane expres-
sion of CD36 was quantified using flow cytometry. Figure 1a
shows that TNFα did not influence membrane expression of
CD36 after 6 h of cell culture in comparison to basal condi-
tions (mean ± SD: 91.8 ± 9.2 versus 94.2 ± 11.2, -4%, p =
0.5). After 12 h, TNFα decreased membrane expression of
CD36 (46.5 ± 6.9 versus 82.9 ± 18.5, -44%, p = 0.04). The
strongest effect was observed after 24 h of cell culture, with a
67% TNFα-induced decrease of CD36 membrane expression
(35.3 ± 15.5 versus 106.9 ± 11.3, p = 0.0004). Monocytes
were then treated with TNFα at increasing concentrations for
24 h. Figure 1b shows that TNFα reduced membrane expres-
sion of CD36 in a dose-dependent manner: -9% (91.6 ± 10.3
versus 100.3 ± 10.9, p = 0.3), -29% (71.2 ± 13.1 versus
100.3 ± 10.9, p = 0.002) and -59% (41.4 ± 4.5 versus 100.3
± 10.9, p = 0.003) for 0.1, 1 and 10 ng/ml TNFα, respectively,
in comparison to basal conditions.
Next, we investigated whether the reduction of membrane
expression of CD36 induced by TNFα could be inhibited by
adalimumab. Figure 1c shows that adalimumab (1 μg/ml)
inhibited the effect of TNFα (10 ng/ml) on membrane expres-
sion of CD36. Furthermore, adalimumab independently
increased membrane expression of CD36 by 59% (194.9 ±
42.3 versus 122.8 ± 23.2, p = 0.03) in the presence of TNFα
and by 90% (233.7 ± 49.7 versus 122.8 ± 23.2, p = 0.04) in
the absence of TNFα, in comparison to basal conditions.
To assess the specificity of adalimumab's effect on membrane
expression of CD36, we used rituximab, a human anti-CD20
IgG1 monoclonal antibody, as a control antibody. Figure 1d
shows that adalimumab increased CD36 membrane expres-
sion (155.3 ± 24.1 versus 97.3 ± 11.7, +60%, p = 7 × 10-5)
while rituximab did not influence it (101.3 ± 18.5 versus 97.3
± 11.7, +4%, p = 0.48), in comparison to basal conditions.
Figure 1e shows that adalimumab did not affect CD36 expres-
sion after 6 and 12 h, while it increased CD36 expression by
92% after 24 h of cell culture (161.5 ± 10 versus 84 ± 12.4,
p = 0.0003) in comparison to basal conditions.
Regulation of CD36 mRNA expression by TNFα and 
adalimumab
To study the effect of TNFα and adalimumab on CD36 mRNA
expression, the monocytes were treated with TNFα or adali-
mumab and the relative quantification of CD36 mRNA was
carried out by RT-PCR. Figure 2 shows that TNFα (10 ng/ml)
reduced CD36 mRNA expression by 72% (mRNA relative
level ± SD: 0.28 ± 0.05, p = 0.002), while adalimumab (1 μg/
ml) increased CD36 mRNA expression by 96% (1.96 ± 0.2, p
= 0.02) in comparison to basal conditions.
Mechanisms involved in the regulation of CD36 
expression by TNFα
Since PPARγ is a transcription factor that plays a key role in
inducing membrane expression of CD36 on human mono-
cytes [19], we investigated its implication in the regulation of
CD36 expression by TNFα. We tested the hypothesis that
PPARγ activation is inhibited by TNFα using gel-shift assays.
The monocytes were incubated with M-SFM alone or with M-
SFM containing TNFα (10 ng/ml) and stimulated, or not, with
a synthetic ligand of PPARγ, rosiglitazone (5 μM), and PPARγ
activation was analyzed by gel-shift assay. Figure 3a shows a
basal activation of PPARγ that was inhibited by TNFα. Rosigl-
itazone increased the activation of PPARγ and this effect of
rosiglitazone was inhibited by TNFα.
To evaluate the consequences of the inhibition of PPARγ acti-
vation by TNFα, we assessed the effect of TNFα on the induc-
tion of CD36 mRNA by rosiglitazone. Monocytes were
incubated with M-SFM alone or with M-SFM containing TNFα
(10 ng/ml) and stimulated, or not, with rosiglitazone (5 μM),
and the relative quantification of CD36 mRNA expression was
carried out by RT-PCR. Figure 3b shows that TNFα reduced
CD36 mRNA expression (-72%, 0.28 ± 0.05, p = 0.002),
while rosiglitazone increased CD36 mRNA expression
(+46%, 1.46 ± 0.2, p = 0.02). The combination of TNFα and
rosiglitazone inhibited the effect of the rosiglitazone by reduc-
ing CD36 mRNA expression (-59%, 0.41 ± 0.2, p = 0.002) in
comparison to basal conditions.
Since redox signaling is involved in the regulation of CD36
expression in human monocytes [21,22], we analyzed its role
in the repression of CD36 membrane expression induced by
TNFα (Figure 3c,d). Monocytes were incubated with TNFα
(10 ng/ml) and ROS production was quantified byAvailable online http://arthritis-research.com/content/9/2/R22
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Figure 1
Regulation of CD36 membrane expression by tumor necrosis factor (TNF)α and adalimumab (Ada) Regulation of CD36 membrane expression by tumor necrosis factor (TNF)α and adalimumab (Ada). (a) TNFα reduces the membrane expression of 
CD36: time course. Human monocytes were incubated with macrophage-serum-free medium (M-SFM) alone (control), or with M-SFM containing 
TNFα (10 ng/ml) for 6 to 12 and 24 h. Membrane expression of CD36 was quantified using flow cytometry. Data represent the geometric mean ± 
standard error (SE) of the fluorescence measured in three experiments in duplicate. *Significantly different from control (p < 0.05). (b) TNFα 
reduces membrane expression of CD36: dose effect. Human monocytes were incubated for 24 h with M-SFM alone (control), or with M-SFM con-
taining TNFα at increasing concentrations (0.1, 1, or 10 ng/ml) for 24 h. Membrane expression of CD36 was quantified using flow cytometry. Data 
represent the geometric mean ± SE of the fluorescence measured in four experiments. *Significantly different from control (p < 0.05). (c) The reduc-
tion of membrane expression of CD36 induced by TNFα is inhibited by adalimumab independently of TNFα. Human monocytes were incubated with 
M-SFM alone (control), or with M-SFM containing either TNFα alone (10 ng/ml), TNFα combined with adalimumab (Ada; 1 μg/ml) or adalimumab 
alone for 24 h. Membrane expression of CD36 was quantified using flow cytometry. Data represent the geometric mean ± SE of the fluorescence 
measured in four experiments. *Significantly different from control (p < 0.05). (d) The increase in CD36 membrane expression induced by adalimu-
mab is antibody-specific. Human monocytes were incubated with M-SFM alone (control), or with M-SFM containing either adalimumab (Ada; 1 μg/
ml), or rituximab (Ritux; 1 μg/ml), a human anti-CD20 IgG1 monoclonal antibody, as a control antibody for 24 h. Membrane expression of CD36 was 
quantified using flow cytometry. Data represent the geometric mean ± SE of the fluorescence measured in four experiments in duplicate. *Signifi-
cantly different from control (p < 0.05). (e) Adalimumab increases membrane expression of CD36: time course. Human monocytes were incubated 
with M-SFM alone (control), or with M-SFM containing adalimumab (Ada; 1 μg/ml) for 6 to 12 and 24 h. Membrane expression of CD36 was quanti-
fied using flow cytometry. Data represent the geometric mean ± SE of the fluorescence measured in three experiments in duplicate. *Significantly 
different from control (p < 0.05).Arthritis Research & Therapy    Vol 9 No 2    Boyer et al.
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chemiluminescence for 1 h. Figure 3c shows that TNFα
induced a two-fold increase in ROS production in comparison
to basal conditions (45,173 ± 3,966 versus 19,207 ± 4,115,
p = 0.03). The role of ROS production in the regulation of
CD36 expression induced by TNFα was analyzed using an
antioxidant. Monocytes were treated with TNFα (10 ng/ml), or
with an antioxidant derived from vitamin E, Trolox® (1 μM), or
with a combination of TNFα and Trolox®. Membrane expres-
sion of CD36 was then quantified using flow cytometry. Figure
3d shows that membrane expression of CD36 was not signif-
icantly modified by Trolox® (76.6 ± 12 versus 86.2 ± 6.8, -
12%,  p  = 0.11) in comparison to basal conditions. TNFα
decreased CD36 expression (35.9 ± 7.8 versus 86.2 ± 6.8, -
52%, p = 1 × 10-5) and this effect was not affected by Trolox®
(42. 3 ± 4 versus 86.2 ± 6.8, -60%, p = 6 × 10-6).
Mechanisms involved in the regulation of CD36 
expression by adalimumab
Since PPARγ is a transcription factor that plays a key role in
inducing membrane expression of CD36 on human mono-
cytes [19], we investigated its implication in the induction of
CD36 membrane expression by adalimumab (Figure 4a). The
monocytes were treated with adalimumab (1 μg/ml) or with a
PPARγ antagonist, GW9662 (2 μM), or with a combination of
adalimumab and GW9662, and CD36 expression was quan-
tified using flow cytometry. Figure 4a shows that adalimumab
increased CD36 membrane expression (233.7 ± 43.7 versus
122.8 ± 23.2, +70%, p = 0.02), while GW9662 did not sig-
nificantly decrease CD36 membrane expression (93.8 ± 31.8
versus 122.8 ± 23.2, -24%, p = 0.2), in comparison to basal
conditions. The combination of adalimumab and GW9662 did
not inhibit the effect of adalimumab on CD36 membrane
expression, which remained increased (205.5 ± 24.3 versus
122.8 ± 23.2, +67%, p = 0.003). We assessed the effect of
Figure 2
Regulation of CD36 mRNA expression by tumor necrosis factor (TNF)α  and adalimumab Regulation of CD36 mRNA expression by tumor necrosis factor (TNF)α 
and adalimumab. TNFα decreases CD36 mRNA expression and adali-
mumab increases CD36 mRNA expression. Human monocytes were 
incubated with macrophage-serum-free medium (M-SFM) alone (con-
trol), or with M-SFM containing TNFα (10 ng/ml) or adalimumab (Ada; 
1 μg/ml) for 4 h. CD36 mRNA expression was quantified using RT-
PCR and normalized to β-actin. Data represent the mean ± standard 
error of the relative quantification of CD36 mRNA expression measured 
in three experiments. *Significantly different from control (p < 0.05).
Figure 3
Mechanisms involved in the regulation of CD36 expression by tumor  necrosis factor (TNF)α Mechanisms involved in the regulation of CD36 expression by tumor 
necrosis factor (TNF)α. (a) TNFα inhibits both basal and rosiglitazone-
induced peroxisome proliferator-activated receptor (PPAR)γ activation. 
Human monocytes were incubated with macrophage-serum-free 
medium (M-SFM) alone (control), or with M-SFM containing TNFα (10 
ng/ml) for 5, 30 or 60 minutes, and then stimulated, or not, with a syn-
thetic ligand of PPARγ, rosiglitazone (R; 5 μmol/l) for 45 minutes. 
Nuclear proteins were isolated and a [γ-32P]ATP labeled oligonucle-
otide expressing the PPAR DNA consensus binding sequence was 
added. PPARγ activation was analyzed by gel-shift assay. (b) TNFα 
inhibits both basal and rosiglitazone-induced CD36 mRNA expression. 
Human monocytes were incubated with M-SFM alone (control), or with 
M-SFM containing TNFα (10 ng/ml) for 1 h and then stimulated or not 
with rosiglitazone (R; 5 μmol/l) for 4 h. CD36 mRNA expression was 
quantified using RT-PCR and normalized to β-actin. Data represent the 
mean ± standard error (SE) of the relative quantification of CD36 
mRNA expression measured in three experiments. *Significantly differ-
ent from control (p < 0.05). (c) TNFα induces reactive oxygen species 
production. Monocytes were incubated with Hanks balanced salt solu-
tion (HBSS) alone (control), or with HBSS containing TNF (10 ng/ml) 
for 1 h. Reactive oxygen species production was measured by chemilu-
minescence in the presence of 5-amino-2,3-dihydro-1,4-phthalazinedi-
one in a thermostatically controlled luminometer. Data represent total 
chemiluminescence emission (area under the curve) for 1 h, measured 
in three experiments. *Significantly different from the control (p < 0.05). 
(d) The decrease in CD36 membrane expression induced by TNFα is 
not inhibited by an anti-oxidant (Trolox). Monocytes were incubated 
with M-SFM alone (control), or with M-SFM containing either TNFα (10 
ng/ml), Trolox® (1 μM), or TNFα combined with Trolox® for 24 h and the 
membrane expression of CD36 expression was quantified using flow 
cytometry. Data represent the geometric mean ± SE of the fluores-
cence measured in three experiments in duplicate. *Significantly differ-
ent from the control (p < 0.05).Available online http://arthritis-research.com/content/9/2/R22
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adalimumab on PPARγ activation and did not observe any
effect in gel shift experiments (data not shown).
To evaluate the role of redox signaling in the induction of
CD36 expression observed with anti-TNFα, monocytes were
incubated with adalimumab (1 μg/ml) and ROS production
was quantified by chemiluminescence for 1 h. Figure 4b
shows that adalimumab induced a two-fold increase in ROS
production in comparison to basal conditions (37,095 ±
1,693 versus 19,207 ± 4,115 p = 0.008). The role of redox
signaling in CD36 expression was investigated by using an
antioxidant. The monocytes were treated with adalimumab (1
μg/ml) or with an antioxidant derived from vitamin E, Trolox® (1
μM), or with a combination of adalimumab and Trolox®, and
membrane expression of CD36 was quantified using flow
cytometry. Figure 4c shows that adalimumab increased CD36
membrane expression (168.6 ± 18.2 versus 86.23 ± 6.8,
+96%, p = 0.001), while Trolox® did not significantly modify it
(76.7 ± 12 versus 86.23 ± 6.8, -11%, p = 0.06), in compari-
son to basal conditions. By contrast, the combination of adal-
imumab and Trolox® inhibited the effect of adalimumab on
CD36 membrane expression, which returned to levels
observed in basal conditions (81.3 ± 17 versus 86.23 ± 6.8,
-6%, p = 0.5).
Since NADPH oxidase is a key enzyme of oxidative metabo-
lism, inducing production of free radicals in monocytes [28],
we investigated its implication in the induction of CD36 mem-
brane expression by adalimumab (Figure 4d). Monocytes were
treated with adalimumab (1 μg/ml) or with an NADPH oxidase
inhibitor, DPI, or with a combination of adalimumab and DPI,
and the membrane expression of CD36 was quantified using
flow cytometry. Figure 4d shows that adalimumab increased
CD36 membrane expression (188.6 ± 46 versus 88 ± 10.9,
+114%, p = 0.002), while DPI decreased it (56.9 ± 4 versus
88 ± 10.9, -35%, p = 0.0003), in comparison to basal condi-
tions. In contrast, the combination of adalimumab and DPI
inhibited the effect of adalimumab on CD36 membrane
expression, which returned to levels observed in basal condi-
tions (108.3 ± 25.4 versus 88 ± 10.9, +23%, p = 0.07).
The biological effects of monoclonal antibodies, such as adal-
imumab, involve both Fab and Fc fragments. The interaction
between the Fc fragments of monoclonal antibodies and the
Fc gamma receptor (FcγR) can activate redox signaling via
NADPH oxidase [29,30]. To investigate the relative contribu-
tions of Fab and Fc fragments in the induction of CD36 mem-
brane expression by adalimumab, we removed the Fc region
from adalimumab through pepsin digestion and isolated the
F(ab')2 region (Figure 5a). The monocytes were treated with
the purified F(ab')2 fragment from adalimumab at an equimolar
concentration to that of 1 μg/ml adalimumab (0.8 μg/ml of
F(ab')2 fragment being equivalent to 1 μg/ml of adalimumab),
and the membrane expression of CD36 was quantified using
flow cytometry. Figure 5b shows that the F(ab')2 fragment of
Figure 4
Mechanisms involved in the regulation of CD36 expression by  adalimumab Mechanisms involved in the regulation of CD36 expression by adalimu-
mab. (a) The increase in CD36 membrane expression induced by adal-
imumab is not inhibited by a peroxisome proliferator-activated receptor 
(PPAR)γ antagonist (GW9662). Monocytes were incubated with mac-
rophage-serum-free medium (M-SFM) alone (control), or with M-SFM 
containing either adalimumab (Ada; 1 μg/ml), GW9662 (GW; 2 μM), 
or adalimumab combined with GW9662 for 24 h, and the membrane 
expression of CD36 was quantified using flow cytometry. Data repre-
sent the geometric mean ± standard error (SE) of the fluorescence 
measured in three experiments in duplicate. *Significantly different from 
the control (p < 0.05). (b) Adalimumab induces ROS production. 
Monocytes were incubated with Hanks balanced salt solution (HBSS) 
alone (control), or with HBSS containing adalimumab (Ada; 1 μg/ml) 
for 1 h. Reactive oxygen species production was measured by chemilu-
minescence in the presence of 5-amino-2,3-dihydro-1,4-phthalazinedi-
one in a thermostatically controlled luminometer. Data represent total 
chemiluminescence emission (area under the curve) for 1 h, measured 
in three experiments. *Significantly different from the control (p < 0.05). 
(c) The increase in CD36 membrane expression induced by adalimu-
mab is inhibited by an anti-oxidant (Trolox). Monocytes were incubated 
with M-SFM alone (control), or with M-SFM containing either adalimu-
mab (Ada; 1 μg/ml), Trolox® (1 μM), or adalimumab combined with 
Trolox® for 24 h and the membrane expression of CD36 was quantified 
using flow cytometry. Data represent the geometric mean ± SE of the 
fluorescence measured in three experiments in duplicate. *Significantly 
different from the control (p < 0.05). (d) The increase in CD36 mem-
brane expression induced by adalimumab is inhibited by a NADPH 
inhibitor (diphenylene iodonium chloride (DPI)). Monocytes were incu-
bated with M-SFM alone (control), or with M-SFM containing either 
adalimumab (Ada; 1 μg/ml), DPI (1 μM), or adalimumab combined with 
DPI for 24 h and the membrane expression of CD36 was quantified 
using flow cytometry. Data represent the geometric mean ± SE of the 
fluorescence measured in three experiments in duplicate. *Significantly 
different from the control (p < 0.05).Arthritis Research & Therapy    Vol 9 No 2    Boyer et al.
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adalimumab increased membrane expression of CD36 (140 ±
20.7 versus 87.5 ± 7.4, +60%, p = 0.005) in comparison to
basal conditions. Finally, we investigated whether the F(ab')2
fragment of adalimumab promoted ROS production. Mono-
cytes were incubated with the F(ab')2 fragment of adalimumab
(0.8 μg/ml) and ROS production was quantified by chemilumi-
nescence for 1 h. Figure 5c shows that the F(ab'2) fragment
induced a two-fold increase in ROS production in comparison
to basal conditions (39,826 ± 6,927 versus 21,873 ± 3,834,
p = 0.01).
Discussion
Our work demonstrates differential regulation of CD36
expression by TNFα and adalimumab in human monocytes.
TNFα inhibits both CD36 membrane expression and mRNA
expression. The inhibition of CD36 expression by TNFα
involves a reduction in PPARγ activation. Adalimumab inde-
pendently increases both CD36 membrane expression and
mRNA expression. The induction of CD36 expression involves
redox signaling via NADPH oxidase activation.
Our study shows that TNFα inhibits both CD36 membrane
expression and mRNA expression in human monocytes. Vari-
ous studies have already shown modulation of CD36 by differ-
ent cytokines. TNFα and IL1 reduce transcription of fatty acid
translocase, homologous to CD36, in hamster adipocytes
[31]. IL4 increases CD36 expression in murine macrophages
[18] and transforming growth factor beta and IL10 reduce
CD36 expression in human macrophages [32,33].
Our study suggests that the inhibition of CD36 expression by
TNFα in human monocytes involves a reduction in PPARγ acti-
vation. A link between PPARγ and membrane expression of
CD36 has already been established in murine macrophages,
where deficiency in 12/15 lipoxygenase, an enzyme necessary
to generate natural PPARγ ligands, led to a reduction in the
expression of CD36 [18]. A reduction in PPARγ activation by
TNFα has already been reported in human adipocytes and
hepatocytes [34,35], but has not yet been documented in
human monocytes. While IL4, a TH2 cytokine, induces CD36
expression via synthesis of natural PPARγ ligands in murine
macrophages [18], we suggest that TNFα, a TH1 cytokine,
inhibits CD36 expression via reduction of PPARγ activation in
human monocytes.
Experimental data show that metabolites produced in an oxi-
dative context increase the expression of CD36 in murine mac-
rophages [21]. We demonstrate here that TNFα, which
induces ROS production, decreases CD36 expression and
that this effect is not altered by antioxidant. These results sug-
gest that ROS production is not involved in the repression of
CD36 induced by TNFα.
Our study shows that adalimumab increases both CD36 mem-
brane expression and mRNA expression in human monocytes.
Figure 5
Role of the Fc portion of adalimumab in the regulation of CD36  expression Role of the Fc portion of adalimumab in the regulation of CD36 expres-
sion. (a) Isolation of F(ab')2, the antigen binding fragment, from adali-
mumab with pepsin digestion. The purity of the F(ab')2 fragment 
obtained was verified by migration of the specimens obtained on a 
12% denaturant acrylamide gel according to the manufacturer's 
instructions. Lane 1 represents the standard molecular weight (20 to 
250 kDa). Lane 2 represents the light chain (25 kDa) and the heavy 
chain (50 kDa) of adalimumab. Lane 3 represents the intact light chain 
(25 kDa) and truncated heavy chain (30 kDa) obtained after pepsin 
digestion. (b) The F(ab')2 fragment of adalimumab increases mem-
brane expression of CD36. Monocytes were incubated with macro-
phage-serum-free medium (M-SFM) alone (control), or with M-SFM 
containing the purified F(ab')2 fragment from adalimumab at an equi-
molar concentration to that of 1 μg/ml adalimumab (0.8 μg/ml of 
F(ab')2 fragment being equivalent to 1 μg/ml of adalimumab) for 24 h 
and membrane expression of CD36 in monocytes was quantified using 
flow cytometry. Data represent the geometric mean ± standard error of 
the fluorescence measured in three experiments in duplicate. *Signifi-
cantly different from the control (p < 0.05). (c) The F(ab')2 fragment of 
adalimumab induces reactive oxygen species (ROS) production. Mono-
cytes were incubated with Hanks balanced salt solution (HBSS) alone 
(control), or with HBSS containing F(ab')2 (0.8 μg/ml) for 1 h. ROS 
production was measured by chemiluminescence in the presence of 5-
amino-2,3-dihydro-1,4-phthalazinedione in a thermostatically controlled 
luminometer. Data represent total chemiluminescence emission (area 
under the curve) for 1 h, measured in three experiments. *Significantly 
different from the control (p < 0.05).Available online http://arthritis-research.com/content/9/2/R22
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This effect is antibody-specific while rituximab, an IgG1 human
antibody directed against CD20, does not influence CD36
membrane expression. The effect of anti-TNFα antibodies on
scavenger receptors had not been evaluated before now. Pre-
vious work reported that certain pharmacological agents,
whose anti-inflammatory properties are used in human ther-
apy, regulate in vitro CD36 expression. Aspirin increases
CD36 expression in lines of human THP1 macrophages [23],
dexamethasone induces CD36 expression in human dendritic
cells from healthy subjects [24] and atorvastatin increases
CD36 expression in human monocytes [36,37].
According to the results of our study, the increase in mem-
brane expression of CD36 induced by adalimumab involves a
redox signaling pathway via NADPH oxidase activation, but
not PPARγ. This is in accordance with previous studies show-
ing that products derived from lipid peroxidation induce tran-
scription of CD36 in murine macrophages by activating
transcription factors, such as Nrf2 [21,38]. On the other hand,
the administration of antioxidants, such as vitamin E, leads to
a reduction in CD36 expression in murine peritoneal macro-
phages, and human endothelial cells, and macrophages
derived from human monocytes [20,22,39].
Although part of the biological effect of antibodies used in
human therapy implicates their binding to FcγR [29,40], and
binding of the Fc fragment to FcγR activates NADPH oxidase
[30,41], the mechanism by which adalimumab increases
membrane expression of CD36 appears independent of its Fc
fragment. Indeed, the induction of CD36 by adalimumab was
specific to the F(ab')2 portion. The F(ab')2 fragment increases
membrane expression of CD36 and induces ROS production,
suggesting that F(ab')2 and native antibody use the same sig-
naling pathway. The slightly lower induction of CD36
expression observed with the F(ab')2 fragment in comparison
to the native antibody could be explained by a partial alteration
of the F(ab')2 fragments during the pepsin digestion process
[42].
We suggest that the F(ab')2 effect on CD36 expression may
partially be the consequence of binding of this fragment of
adalimumab to transmembrane TNFα. This binding leads to
the activation of various intracellular signaling pathways, in
particular calcium-dependant pathways, and play a role in the
biological activity of anti-TNFα monoclonal antibodies [43,44].
Such a reverse signaling phenomenon, resulting from the bind-
ing of adalimumab to transmembrane TNFα, could account for
the differential regulation of CD36 expression by TNFα and
adalimumab in human monocytes [45].
Differential regulation of CD36 expression by TNFα and adal-
imumab in human monocytes may have consequences on the
high cardiovascular mortality observed in chronic inflammatory
diseases such as RA. In such conditions, anti-TNFα agents
appear to reduce the incidence of cardiovascular events [5].
In addition to their anti-inflammatory effect, which seems ben-
eficial in atherosclerosis, anti-TNFα agents could correct
endothelial dysfunction and lipid profile abnormalities reported
in chronic inflammatory diseases [11,46]. The increase in
CD36 expression induced by adalimumab reported in our
study could contribute to the modulation of cardiovascular risk
under anti-TNFα therapies. In murine models of atherosclero-
sis, ApoE-/- mice, the consequences of inactivating the gene
encoding CD36 remain contradictory: a decrease in the for-
mation of atheroma plaques in one case [47], and an increase
in the size of atheroma plaques in another [48]. In humans,
subjects naturally deficient in CD36 show greater atheroscle-
rosis, which suggests CD36 has an anti-atherogenic role [49].
The increase in CD36 expression induced in vitro by pharma-
cological agents such as aspirin and atorvastatin, whose anti-
atherogenic effects are clearly established in human therapy,
would suggest that this may be the case [23,37].
Conclusion
Our work demonstrates differential regulation of CD36
expression by TNFα and adalimumab in human monocytes.
While TNFα inhibits both CD36 membrane expression and
mRNA expression, an anti-TNFα monoclonal antibody, adali-
mumab, independently increases both CD36 membrane
expression and mRNA expression. Better understanding of the
impact of anti-inflammatory therapeutic agents, such as anti-
TNFα, on scavenger receptors, such as CD36 and SRA, and
membrane reverse cholesterol transporters, such as ATP-
binding cassette transporters A1 (ABCA1), may have implica-
tions for the prevention of high cardiovascular mortality
observed in chronic inflammatory diseases.
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